1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA Consults On Integrating Needs Of Older People Into Drug Development

 
• By Vibha Sharma

The European Medicines Agency has explained how companies developing medicines for older people can better address the needs of this patient population.

Pills
Drug Makers Are Being Encouraged To Keep In Mind The Needs Of Older People • Source: Shutterstock

The European Medicines Agency is inviting feedback on a draft reflection paper that discusses how drug companies could improve the way they develop and package medicines for older people, who may face difficulties that can result in medicines not being taken as intended, medication errors and ultimately a reduced quality of life.

Even though older people are considered the highest users of medicines and are at the highest risk of encountering usability...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

‘Clean Sweep’ Of US CDC Vaccine Committee Puts Kennedy In Driver’s Seat

 
• By Bridget Silverman

With a 25-27 June meeting looming, HHS Secretary Robert F. Kennedy Jr. can fill all 17 spots on the CDC's Advisory Committee on Immunization Practices with people he says will "exercise independent judgment."

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Orphan Drug Trial Sponsors ‘Playing Catch-Up’ With Regulators – But Automation Can Help

 
• By Eliza Slawther

Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.